The Effects of Ezetimibe on Surrogate Markers of Cholesterol Absorption and Synthesis in Japanese Patients with Dyslipidemia
| Autor: | Yukio Ozaki, Kenji Yamada, Satoshi Yoshida, Hitoshi Hishida, Shinya Hiramitsu, Manji Noba, Hiroyuki Matsuyama, Akihisa Uemura, Yoshiaki Ishiguro, Kazuo Kato, Yoshiro Matsubara, Kazuo Hasegawa, Atsushi Kani |
|---|---|
| Rok vydání: | 2010 |
| Předmět: |
Blood Glucose
Male medicine.medical_specialty Statin medicine.drug_class Carbohydrate metabolism chemistry.chemical_compound Asian People Ezetimibe Risk Factors Internal medicine Internal Medicine medicine Humans Insulin Obesity Adverse effect Triglycerides Aged Dyslipidemias Glycated Hemoglobin business.industry Cholesterol Anticholesteremic Agents Cholesterol HDL Biochemistry (medical) Cholesterol LDL Middle Aged medicine.disease C-Reactive Protein Endocrinology chemistry Intestinal cholesterol absorption Azetidines Drug Therapy Combination Female lipids (amino acids peptides and proteins) Hydroxymethylglutaryl-CoA Reductase Inhibitors Cardiology and Cardiovascular Medicine business Biomarkers Dyslipidemia medicine.drug |
| Zdroj: | Journal of Atherosclerosis and Thrombosis. 17:106-114 |
| ISSN: | 1880-3873 1340-3478 |
| DOI: | 10.5551/jat.1578 |
| Popis: | Aim: To demonstrate the clinical benefit of inhibiting intestinal cholesterol absorption, we evaluated the effects of ezetimibe on surrogate markers of cholesterol absorption and synthesis, lipid and glucose metabolism, and markers of obesity and inflammation.Methods: A total of 120 patients with dyslipidemia (46 men; mean age 66.5 years), who had not achieved the low density lipoprotein cholesterol (LDL-C) goal recommended by the Japan Atherosclerosis Society Guideline despite diet and exercise or any statin therapy, were enrolled and additionally treated with ezetimibe (10 mg/day) for 12 weeks.Results: Compared to the baseline, LDL-C was reduced by 19.2% (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|